{"organizations": [], "uuid": "fbc5e5f974630c0b5e9eba2cf252abc79bdce51f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180110.html", "section_title": "Archive News &amp; Video for Wednesday, 10 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-gensight-biologics-obtains-authori/brief-gensight-biologics-obtains-authorization-of-mhra-to-start-clinical-study-of-phase-i-ii-pioneer-of-gene-therapy-gs030-idUSFWN1P412P", "country": "US", "domain_rank": 408, "title": "BRIEF-Gensight Biologics Obtains Authorization Of Mhra To Start Clinical Study Of Phase I/II Pioneer Of Gene Therapy GS030‍​", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.955, "site_type": "news", "published": "2018-01-10T14:43:00.000+02:00", "replies_count": 0, "uuid": "fbc5e5f974630c0b5e9eba2cf252abc79bdce51f"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-gensight-biologics-obtains-authori/brief-gensight-biologics-obtains-authorization-of-mhra-to-start-clinical-study-of-phase-i-ii-pioneer-of-gene-therapy-gs030-idUSFWN1P412P", "ord_in_thread": 0, "title": "BRIEF-Gensight Biologics Obtains Authorization Of Mhra To Start Clinical Study Of Phase I/II Pioneer Of Gene Therapy GS030‍​", "locations": [], "entities": {"persons": [{"name": "gensight", "sentiment": "negative"}], "locations": [{"name": "uk", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "mhra", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 10 (Reuters) - GENSIGHT BIOLOGICS SA:\n* GENSIGHT OBTAINS AUTHORIZATION OF MHRA TO START CLINICAL STUDY OF PHASE I/II PIONEER OF GENE THERAPY GS030‍​\n* EXPECTS TO TREAT FIRST PATIENT IN UK IN Q1 2018‍​‍​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\nOur Standards: The Thomson Reuters Trust Principles.", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-10T14:43:00.000+02:00", "crawled": "2018-01-11T12:26:52.006+02:00", "highlightTitle": ""}